Synonyms: SAR-245409 | SAR245409 | XL765
Compound class:
Synthetic organic
Comment: Voxtalisib is an orally bioavailable small molecule inhibitor of phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity [1].
|
|
No information available. |
Summary of Clinical Use |
ClinicalTrials.gov has 11 registered voxtalisib (XL765) trials, with a maximum phase 2. None of these trials are active as of October 2018. Click here to link to ClinicalTrials.gov's full list of voxtalisib trials. |